The conversation around GLP-1 receptor agonists has never been louder. Semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and their peers have moved from specialty clinics to dinner tables. Patients are asking. Insurers are debating. Headlines swing between "miracle drug" and "dangerous shortcut." As a clinician, my job is to separate the headlines from the evidence and give patients a grounded answer.
Here is mine: GLP-1s are a legitimate and sometimes highly effective tool, but they are not the foundation of lasting health. That foundation is lifestyle change.
What the two biggest trials found
The data on GLP-1 receptor agonists for obesity is worth examining directly, without the hyperbole that tends to follow it into headlines. Two trials in particular established what these medications can do at their best.
The STEP 1 trial demonstrated that semaglutide 2.4 mg produced an average body weight reduction of approximately 15% over 68 weeks compared to placebo. That magnitude had previously been associated with bariatric surgery, not a weekly injection (Wilding et al., NEJM, 2021).
The SURMOUNT-1 trial of tirzepatide went further. Some participants lost more than 20% of body weight, and average reductions exceeded what semaglutide had achieved in its own trials (Jastreboff et al., NEJM, 2022). To put numbers on that: a person weighing 250 pounds could expect to lose roughly 37 pounds on semaglutide and 50 or more on tirzepatide, depending on individual response. The medical community took notice.
What goes beyond the scale
Beyond weight, both drug classes have demonstrated meaningful improvements in blood pressure, lipid profiles, and HbA1c. The SELECT trial, which studied semaglutide in people with obesity and established cardiovascular disease, reported a 20% reduction in major adverse cardiovascular events (Lincoff et al., NEJM, 2023).
That finding repositioned these medications in clinical thinking. They had been categorized as weight loss tools. The SELECT data put them in conversation with medications that carry demonstrated cardiovascular protection. For certain patients, the case for a prescription goes beyond cosmetic or functional weight goals.
The two drugs, side by side
Semaglutide and tirzepatide are sometimes discussed as interchangeable. They work differently, and those differences shape the clinical conversation. Tap each to see how.
Semaglutide is a GLP-1 receptor agonist. It mimics glucagon-like peptide-1, a gut hormone that signals fullness to the brain, slows gastric emptying, and reduces appetite. Ozempic (0.5 to 2 mg weekly) was initially approved for type 2 diabetes. Wegovy (2.4 mg weekly) received FDA approval for chronic weight management in adults with a BMI of 30 or above, or 27 with a weight-related condition. The STEP 1 trial, in about 1,900 participants, produced the approximately 15% average weight reduction that established semaglutide's role in obesity medicine.
Tirzepatide is a dual agonist, acting on both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. GIP is a second gut hormone involved in insulin secretion and fat metabolism, and the combined mechanism appears to amplify weight loss beyond what GLP-1 alone produces. Mounjaro (up to 15 mg weekly) was first approved for type 2 diabetes. Zepbound received FDA approval for weight management. The SURMOUNT-1 trial in over 2,500 adults showed average reductions of 15 to 21% depending on dose, with some participants exceeding 22%.
Head-to-head data consistently shows tirzepatide producing greater weight loss than semaglutide at comparable doses. Side effect profiles overlap for both: nausea, vomiting, diarrhea, and constipation are common, particularly during dose escalation. Both require weekly subcutaneous injections. Cost and insurance coverage vary considerably by plan, and access has been inconsistent given ongoing supply challenges. Neither drug has long-term safety data much beyond four to five years.
Both medications produce their best results when paired with meaningful lifestyle change. Both are associated with significant weight regain when discontinued. Both suppress appetite without addressing the behavioral, psychological, or environmental factors that contribute to obesity. And both require a conversation with a qualified provider about whether the clinical criteria are met, whether the patient is prepared to do the behavioral work alongside medication, and what realistic expectations look like.
Why weight loss alone is not enough
Despite the compelling clinical data, I do not recommend a prescription as a first response. Here is why.
Weight loss without behavior change rarely lasts. When GLP-1 medications are discontinued, the majority of weight returns within one year, according to a study following semaglutide cessation (Wilding et al., Diabetes, Obesity and Metabolism, 2022). The medication suppresses appetite. It does not rebuild a relationship with food, address the psychological or social drivers of obesity, or create the habits that carry someone forward after the prescription ends. If those go unaddressed, the underlying problem has not been treated.
My approach is lifestyle first, always. Structured dietary changes, consistent physical activity, sleep optimization, and stress reduction remain the most durable interventions available. For patients who have engaged seriously with those strategies and still face significant obesity, particularly with metabolic complications, GLP-1s become a meaningful part of the conversation.
"GLP-1 medications solve the obesity problem."
They address one part of it: appetite suppression. The behavioral, psychological, and environmental contributors to obesity remain unchanged unless directly addressed. Medication without behavior change tends to produce temporary results and a return to baseline once the prescription ends.
What GLP-1 medications address, and what they don't
This is where I spend the most time with patients. Use the toggle to see both sides of the picture.
When I support GLP-1 therapy
GLP-1 medications are not appropriate for everyone. These are the conditions I look for before supporting them with a patient.
I support initiating GLP-1 therapy when:
- BMI is 30 or above, or 27 or above with a weight-related condition such as hypertension, type 2 diabetes, or obstructive sleep apnea
- The patient has made sincere, structured lifestyle efforts without sufficient response
- There is a shared understanding that medication is an adjunct to behavioral change, not a replacement for it
- Side effects, cost, long-term expectations, and the likelihood of needing continued use have been discussed openly and honestly
These are not rigid gatekeeping criteria. They are a clinical framework for identifying the patients most likely to benefit and least likely to be disappointed by what the medication can and cannot do.
Check the clinical criteria
BMI is one component of the clinical picture. It is an imperfect measure that does not account for muscle mass, body composition, or where weight is distributed, but it remains the primary threshold in clinical criteria for GLP-1 eligibility. Enter your height and weight to see where you land relative to those thresholds.
BMI Quick-Check
Based on current FDA-approved eligibility criteria for GLP-1 weight management medications.
A bridge, not a destination
When I do support GLP-1 therapy, I frame it this way with patients: this is a bridge, not a destination. The reduced appetite and early weight loss create a window of physiological opportunity. The goal is to use that window to build the habits that will carry a patient forward, whether the medication is eventually discontinued or the dose adjusted over time.
That means investing in the work during treatment. Dietary counseling to rebuild a relationship with food. Resistance training to protect lean mass. Addressing sleep and stress, which influence appetite and metabolism independently of any medication. The patients who do best on these drugs are the ones who use them to go further than lifestyle alone could have taken them in a reasonable timeframe, and then have the foundation to hold that progress.
Are you ready for this conversation with your provider?
GLP-1 therapy is a clinical decision, and this quiz is not a substitute for that. It can, however, help you think through where you stand relative to the criteria that matter most, so you can go into that conversation with more clarity.
Five-Question GLP-1 Readiness Check
Answer based on your current situation, not where you hope to be.
My clinical bottom line
GLP-1 receptor agonists, semaglutide, tirzepatide, and the drugs that will follow them, are among the most significant developments in obesity medicine in decades. The trial data is credible. The cardiovascular findings in SELECT are harder to dismiss than weight loss numbers alone. For the right patient, with the right clinical picture and a genuine commitment to the behavioral work, these medications can help someone reach outcomes that lifestyle alone would have taken considerably longer to achieve.
What I want my patients to hold onto is this: a medication that suppresses appetite is doing something real, but it is not doing everything. The behaviors that contributed to the problem in the first place are still there when the injection wears off. A prescription that works for a year and leads to full weight regain upon stopping is a temporary result, not a solved problem. That is why I insist on lifestyle first, and on active habit-building during treatment.
Used thoughtfully, in the right patient, alongside sustained work on food relationships and physical activity, these medications can move someone further than lifestyle alone could in a reasonable window of time. That is where the value is, and that is how I try to use them.
Get nutrition support built around your situation
Whether you are considering GLP-1 therapy or want to build the foundation first, a Registered Dietitian can help you think through what makes sense for your body, your labs, and your goals.
Start your assessment